GlassScriptPhysician profile
Thomas A Pavlovic
NPI 1619042785
$7,541.14
in general payments reported to CMS, 2019-2025
33 companies · $927 in 2025
The $927 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $682 · 2021: $1,545 · 2022: $932 · 2023: $1,561 · 2024: $913 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,917 · Consulting Fee: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,916.61 |
| Consulting Fee | $485.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,466.40 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $756.64 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $647.84 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $614.77 | 2019-2024 | Opsumit, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $530.89 | 2019-2025 | Jardiance |
| Pfizer INC. | $521.85 | 2019-2025 | |
| Medtronic, INC. | $496.21 | 2021-2023 | Micra |
| Astrazeneca Pharmaceuticals LP | $396.81 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Esperion Therapeutics, INC. | $307.68 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $287.92 | 2019-2024 | Camzyos, Eliquis |
| Amgen INC. | $186.39 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $185.81 | 2021-2025 | Onpattro |
| Medicure Pharma INC. | $146.12 | 2019-2020 | |
| Baxter Healthcare | $114.39 | 2023 | |
| Boston Scientific Corporation | $100.72 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.24 | 2019-2025 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $88.07 | 2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $74.76 | 2019-2021 | |
| Astellas Pharma US INC | $71.83 | 2020-2022 | |
| Edwards Lifesciences Corporation | $67.10 | 2020-2022 | |
| Watermark Medical, INC. | $65.53 | 2022 | |
| Heartflow, INC. | $46.40 | 2024 | |
| Chiesi USA, INC. | $37.67 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $32.83 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $30.05 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $26.94 | 2019-2020 | |
| Innovation Technologies INC | $24.89 | 2022 | |
| Csl Behring | $22.92 | 2023 | Kcentra |
| Regeneron Healthcare Solutions, INC. | $22.91 | 2019 | |
| Amarin Pharma, INC. | $22.72 | 2020 | |
| Lantheus Medical Imaging, INC. | $22.56 | 2020 | |
| Medtronic Vascular, INC. | $14.71 | 2020 | |
| Biotronik INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Pavlovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.